Man Group
CAI

Man Group’s Caris Life Sciences CAI Stock Holding History

Man Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Buy
+128,971
New +$2.82M ﹤0.01% 1517
2025
Q4 		– Sell
-16,078
Closed -$486K – 2546
2025
Q3 		$486K Buy
+16,078
New +$513K ﹤0.01% 1860

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Man Group's CAI Position: Q1 2026 in Review

Man Group opened a new position in Caris Life Sciences (CAI) in Q1 2026: 128,971 shares worth $2.31M. The stake represents ﹤0.01% of the portfolio and ranks #1517 among its holdings. This is a return to the name: Man Group previously reported a position in CAI as recently as Q3 2025.

Man Group first reported a position in CAI in Q3 2025 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Man Group held 128,971 shares of Caris Life Sciences worth $2.31M as of Q1 2026.
  • Caris Life Sciences was a new Man Group position in Q1 2026.
  • Caris Life Sciences made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1517 holding.
  • Man Group first reported a position in Caris Life Sciences in Q3 2025 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.